Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple Chest-and-Arm patch replace bulky heart monitors?

NCT ID NCT07694570

Knowledge-focused Sponsor: University Hospital, Basel, Switzerland Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This study tests a new wearable system called M2VS that measures heart activity (ECG) and blood pressure continuously for 24 hours. Researchers want to see if it works as well as standard monitors like Holter ECG and ambulatory blood pressure monitors. The study involves 20 adults with atrial fibrillation or hypertension who already need 24-hour monitoring. The goal is to check how reliable and comfortable the M2VS system is compared to current devices.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
M2VS system (wearable sensor with belt)
What this could lead to
If successful, this could lead to more comfortable and convenient ways to monitor heart rhythm and blood pressure continuously during daily life.
What could go wrong
This is a small feasibility study (20 participants) focused on data quality and comfort, not on treating or diagnosing disease. The device may not prove accurate enough to replace standard monitors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The project population consists of adult participants (≥18 years) recruited at the USB who have a clinical indication for either 24-hour Holter monitoring or 24-hour ABPM. A total of N=20 participants will be enrolled, N=10 for the Holter cohort and N=10 for the ABPM cohort.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Written informed consent obtained prior to any project-specific procedures. * Age 18 years or older at the time of enrolment. * Ability to provide valid informed consent. * Clinical indication for 24-hour Holter monitoring (Holter cohort) or 24-hour ABPM (ABPM cohort). Exclusion Criteria: * Insufficient knowledge of the German language, preventing adequate understanding of the project procedures and informed consent. * Enrolment of the project leader, project staff, their family members, employees, or other dependent persons. Dermatological and Sensor Placement: * Pre-existing skin conditions at the application sites (medial upper arm or chest), such as extensive scarring, tattoos, open wounds, active inflammation, or severe oedema that could interfere with sensor coupling or signal quality. * Excessive hair at the application site that could interfere with sensor coupling or signal quality. * Presence of other concurrent wearable devices at the same anatomical application site that could interfere with the M2VS system. * Known allergy to skin-contacting materials utilized in the M2VS system.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrial fibrillation (paroxysmal) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atrial fibrillation hypertensive disorder paroxysmal atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atrial fibrillation (paroxysmal) Hypertension

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University Hospital Basel

    Basel, Canton of Basel-City, 4031, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.